Feds Eye Tougher Oversight Of Deals Blocking Biosimilars
The Federal Trade Commission may finally be ready to crack down on potentially anti-competitive deals that keep costly biologic drugs' cheaper equivalents off pharmacy shelves....To view the full article, register now.
Already a subscriber? Click here to view full article